logo munafa.co.com

NEWS Gainers Losers
 Learn then Earn

 story : Moderna says its COVID-19 vaccine has a 96% efficacy rate in teens who have received one shot #FinanceUSA #StockMarketNEWS Moderna Inc. said Thursday that initial data from the study evaluating its

@stockMarketNEWS Thu 06 May, 2021

Posted in: #FinanceUSA #StockMarketNEWS

Moderna says its COVID-19 vaccine has a 96% efficacy rate in teens who have received one shot #FinanceUSA #StockMarketNEWS
Moderna Inc. said Thursday that initial data from the study evaluating its COVID-19 vaccine in teens between the ages of 12 and 17 years old showed an efficacy rate of 96%, with no serious safety concerns. The Phase 2/3 clinical trial is testing the vaccine in 3,235 teens who have received at least one shot in the two-dose regimen and have not previously been infected with SARS-CoV-2. "Because the incidence rate of COVID-19 is lower in adolescents, the case definition is less stringent ... resulting in vaccine efficacy against milder disease," Moderna said in its earnings release. Pfizer Inc. is expected to have its emergency authorization for its COVID-19 vaccine expanded sometime in the next week to include 12 to 15 year olds. Data from Pfizer's study showed an efficacy rate of 100% in 2,260 teens who have had or not had COVID-19. Moderna's stock is up 55.8% for the year, while the S&P 500 has gained 10.9%.


Munafa USA Munafa India Munafa NSE


Report

Munafa ebook, learn stock market trading

0 Comments

Sorted by latest first Latest Oldest Best

 Learn then Earn
Back to top | Use Dark Theme